Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135135 · ClinicalTrials.gov registry record · Phase 2
Therapy for Children With Neuroblastoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00135135 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 23 participants.
The verdict
NCT00135135, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell transplantation, and an oral maintenance phase with 13-cis-retinoic acid and topotecan. We hypothesize that the ZD1839 (gefitinib) and irinotecan window will be efficacious.
Interventions
- DRUG Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid
- PROCEDURE Radiation therapy, Surgery, Peripheral Stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135135
The ClinicalTrials.gov registry entry for NCT00135135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid is the first listed.
NCT00135135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135135 about?
NCT00135135 is a clinical study titled "Therapy for Children With Neuroblastoma". This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell transplantation, and an oral maintenance phase with 13-cis-retinoic acid and topotec...
What is the current status of trial NCT00135135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2005-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00135135?
The interventions under investigation include: Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid (DRUG), Radiation therapy, Surgery, Peripheral Stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00135135?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.